This is an excellent article on the feasibility of offering Veno Arterial ECMO in outlying community hospitals for Refractory Cardiogenic Shock (RCS). The Authors review a four year time period and describe assessing 104 patients of whom 87 were deemed eligible for V-A ECMO therapy.
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Emergency circulatory support in refractory cardiogenic shock patients in remote institutions: a pilot study (the cardiac-RESCUE program)
December 1, 2014
November 15, 2014
Selzman and colleagues provide an outstanding overview of the state of the art of bridge to recovery, describing a paradigm shift that has been occurring. A consistent theme over the years is that recovery likelihood is enhanced in younger patients, those with non-ischemic cardiomyopathy, and those who have had HF for shorter durations.
November 10, 2014
The authors explored a sample of Medicare patients who survived sepsis during hospitalization to assess the impact of afib developing during sepsis on long-term outcomes. Of nearly 139,000 sepsis survivors, 7% had new onset afib during sepsis. Of those pts, 55% were found to have afib after hospitlization. New onset afib during sepsis was associat
Effect of Exercise and Pump Speed Modulation on Invasive Hemodynamics in Patients with Centrifugal Continuous Flow Left Ventricular Assist Devices
November 10, 2014
The effects of exercise, increasing pump speed, or both on invasive hemodynamics in centrifugal flow LVAD patients were analyzed in this small study. Findings included:
Heart Failure Readmission After Mitral Valve Repair and Replacement: Five-Year Follow-Up in the Medicare Population
November 5, 2014
The authors explored readmission rates for heart failure after MV repair/replacement in the US Medicare population as a means for assessing quality. The preop heart failure rate in this population was 61%. Readmission rates were 25% at 30 days and 78% at 5 years; they were substantially higher for those with preop heart failure and were higher for
James Needs a Heart , follow his story and promote awareness with the charity 'Live Life then Give Life'
November 2, 2014
All about James Hello, my name is James Lewis. I am 4 years old. I have been waiting for a heart transplant for 9 months. I have a heart condition called restrictive cardiomyopathy, which means that my heart does not work properly anymore.
Surgical Septal Myectomy Versus Alcohol Septal Ablation: Assessing the Status of the Controversy in 2014
October 31, 2014
In this review, the authors describe alternative treatments for hypertrophic cardiomyopathy (HCM). The most important evidence comparing alcohol septal ablation (ASA) and surgical myectomy is discussed. The authors conclude that surgery is most consistent in achieving optimal hemodynamic results, quality of life and longevity.
September 9, 2014
This video demonstrates a heart transplantation in a patient with an LVAD.
Survival on the Heart Transplant Waiting List: Impact of Continuous Flow Left Ventricular Assist Device as Bridge to Transplant
September 4, 2014
The impact of continuous flow VAD on survival among patients awaiting heart transplant is not well known. Pts on the UNOS list were propensity score matched 1:2 (HeartMate II vs no VAD). Wait list mortality was 10% during the 7.5 year study. Use of a VAD improved survival to transplant at 1 (91% vs 77%) and 2 years (85% vs 68%). Use of VAD as a br
August 18, 2014
Bioprinting, the production of tissue by 3D printing, is a rapidly emerging technology with high potential for tissue engineering also in cardiac surgery. The paper provides insight in currently available techniques, opportunities for application and perspectives of this revolution in medicine.